Quadrant purchase adds CME muscle

Share this article:
Quadrant HealthCom plans to beef up its med ed offering through four titles recently acquired from Jobson.

“The idea is to integrate them into Quadrant and try to give them the kind of support they need to realize their potential,” said Steve Stoneburn, president and CEO of Quadrant. “We're optimistic we can continue to grow that business.”

The acquisitions broaden Quadrant's audience to 500,000 readers across 13 titles, bolstering its primary care portfolio and giving it entrée into the neurology, psychiatry, pulmonary and NP/PA specialty categories. The four titles include Clinician Reviews, Neurology Reviews, Neuropsychiatry Reviews and Pulmonary Reviews.

A fifth title included in the deal, Women's Health in Primary Care, will cease publication, with elements to be added to Quadrant's The Female Patient. Editor-in-chief Maura Griffith will serve as chief of content development activities at Quadrant Medical Education.

Roland DeSilva of DeSilva + Phillips, which brokered the deal for Quadrant, called it “an excellent strategic fit for Quadrant.”

Stoneburn said great synergies exist between the titles. “We've begun to develop a series of market-specific publications under the banner of Women's Health In…that utilizes the women's health content and branding but focus on more narrowly defined subjects,” he said.

Terms of the deal were not disclosed.

Share this article:
close

Next Article in News

Email Newsletters

More in News

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.

Amgen Q2 sales rise, company to lay off up to 2,900

Amgen Q2 sales rise, company to lay off ...

The majority of the layoffs will be in the US.

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...